Laker,
I think you nailed it. This is a trust issue. For me, this is the first significant COR event by management that has required a true leap of faith; unlike many on this board, Stoll's handling of the FDA hold and the January financing made sense to me. But this...my gut says it either portends something really good (dealing from strength, advancing other compounds, etc) or really bad (CX717 trouble). And when I'm "unclear" about my money, I don't make a move. I want to hear what he has to say - and what he doesn't say - in the CC.
R
Market Data 
Markets 
AI
